A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Protocol: 
AAAR4631
Phase: 
II

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

The purpose of this study is to see if the newly discovered vaccine drug,
DSP-7888, will help your immune system to fight against cancer cells that
have a protein called WT1.

The study will also compare the effectiveness of treatment with DSP-7888 in
combination with Bevacizumab versus Bevacizumab alone in patients with
glioblastoma (GBM). Bevacizumab has been approved by the FDA to treat GBM.

Are you Eligible? (Inclusion Criteria)

Patient must:
1. Have histologically confirmed diagnosis of supratentorial GBM (Grade 4
astrocytoma)
2. Have had no prior therapy with Bevacizumab
3. Be 18 years or older
4. Be able to live at home and care for most personal needs

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States